Icagen institutional investors call Pfizer's $56M offer inadequate

08/14/2011 | MedCityNews.com

Merlin Nexus and New Leaf Venture Partners, Icagen's institutional investors, reiterated their opposition to Pfizer's $56 million offer for the drugmaker, saying the bid is inadequate. Icagen, which is developing painkillers, should be priced $11 to $19 a share, or $100 million to $165 million, the investors said in a letter to Icagen's board of directors.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX